FAKTOR-OPTIONSSCHEIN - KENVUE Share Price

Certificat

DE000MB7SFH3

Delayed Börse Stuttgart 01:19:55 01/07/2024 pm IST
0.66 EUR -1.49% Intraday chart for FAKTOR-OPTIONSSCHEIN - KENVUE
Current month-30.21%
1 month-31.63%
Date Price Change
01/24/01 0.66 -1.49%
28/24/28 0.67 -9.46%
27/24/27 0.74 -3.90%
26/24/26 0.77 -1.28%
25/24/25 0.78 -6.02%

Delayed Quote Börse Stuttgart

Last update July 01, 2024 at 01:19 pm IST

More quotes

Static data

Product typeProductos Exóticos
Buy / SellCALL
Underlying KENVUE INC.
Issuer Morgan Stanley
WKN MB7SFH
ISINDE000MB7SFH3
Date issued 21/06/2023
Strike 14.55 $
Maturity Unlimited
Parity 4.99 : 1
Emission price 10
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 10.66
Lowest since issue 0.65
Spread 0.07
Spread %9.59%

Company Profile

Kenvue Inc. is one of the world leaders in the design, manufacture and marketing of consumer healthcare products. The group offers products for health, beauty, baby care, oral care, skin care and more. The business is organized around 3 product families: - health products: for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.); - body care products: hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.); - other: notably oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.). Product marketing is assured through direct sales, distributors and the Internet.
Sector
-
More about the company

Ratings for Kenvue Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Kenvue Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
18.18 USD
Average target price
22.54 USD
Spread / Average Target
+23.97%
Consensus